Acarix (ACARIX.ST) Stock Analysis & AI Equity Report
Acarix (ACARIX.ST) overview
Acarix (ACARIX.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Acarix reported revenue of SEK 7.4m and operating profit of SEK -48.0m; the year-end share price was 0.27 SEK and market capitalisation was SEK 302m. Acarix is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Acarix's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Acarix
Acarix AB is a Swedish medical device company that develops and commercializes the CADScor System, a point-of-care diagnostic aid for assessing the risk of coronary artery disease in patients with chest pain. The system uses acoustic measurements and computational processing to support early risk stratification and help guide further cardiac evaluation.
Generate the Acarix report
Acarix is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Acarix and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Acarix
Each is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by what other analysts said the work added over the engine's report — a score out of five from people who had to read it to give it.